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Abstract Overexpression of c-Abl tyrosine kinase can be 
growth inhibitory in certain fibroblast cell lines. Using a series 
of conditional chimeras between Abl and Src, we have now 
further dissected the Abl protein to determine which domains are 
required for this function. We found that growth inhibition, 
unlike transformation by oncogenie forms of Abl, is dependent on 
the presence of the cognate SH2 and tyrosine kinase domains. 
Since growth inhibition correlates with low tyrosine kinase 
activity, it may involve highly specific interactions of target 
proteins with both domains without the processivity of phosphor- 
ylation associated with oncogenic Abl. 
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1. Introduction 
The c-abl proto-oncogene encodes a nuclear and cytoplas- 
mic non-receptor tyrosine kinase which contains the Src- 
homology domains SH3, SH2 (phosphotyrosine binding do- 
main) and SH1 (tyrosine kinase domain) [1]. The majority of 
our knowledge on Abl derives from studies on numerous on- 
cogenic variants. In contrast, he function of the cellular c-Abl 
is poorly understood, but several recent observations have 
suggested a role in the regulation of cell proliferation and 
differentiation. (1) In Drosophila, Abl has been genetically 
implicated in the regulation of cell--cell interactions [2]. (2) 
Mammalian c-Abl is associated with the retinoblastoma pro- 
tein Rb which inhibits its tyrosine kinase activity and, con- 
versely, overexpression f c-Abl can overcome an Rb-induced 
growth arrest; moreover, Abl tyrosine kinase is activated ur- 
ing the G1-S transition upon release from the phosphorylated 
form of Rb [3,4]. (3) Overexpression f wild-type c-Abl [5,6], 
retroviral v-Abl [7-9] as well as various derivatives thereof 
[6,10,11] can inhibit the proliferation of murine fibroblast 
cells; this activity appears to depend on p53 and Rb [12,13]. 
(4) c-Abl may be involved in the cellular response to DNA- 
damaging agents [14,15] which is associated with a cell cycle 
arrest. 
We have previously demonstrated that regulable Abl-estro- 
gen receptor (Abl :ER) fusion proteins can be used to facilitate 
the analysis of the growth inhibitory function of Abl [10]. 
Abl:ER chimeras can be reversibly switched from their trans- 
forming to their growth inhibitory mode by removal of estro- 
gens. This system allowed us to show that growth inhibition 
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correlates with low tyrosine kinase activity of hypo-phos- 
phorylated Abl proteins. Moreover, we found that Abl effects 
a cell cycle arrest by blocking cells early in G1. 
Relatively little is known about the structural requirements 
for growth inhibition. Of the three Src-homology domains, 
the SH3 domain is dispensable: it is absent from some of 
our growth inhibitory Abl:ER chimeras [10,11] and from 
v-AN [9]. In contrast, point mutations that inactivate the 
phosphotyrosine binding activity of SH2 or the tyrosine ki- 
nase activity abolish both the transforming and the growth 
inhibitory functions of Abl [6,13]. Furthermore, the nuclear 
localization signal at amino acids 624-628 and the C-terminal 
half of c-Abl, comprising residues 631 1142, are not strictly 
required for growth inhibition [10] although the latter may 
play an auxilliary or non-specific role in the context of wild- 
type c-AN [10,13]. Thus, these results uggested that the SH2 
and tyrosine kinase domains are essential. We now present a
further analysis of the contributions of the SH2 and tyrosine 
kinase domains of Abl to growth inhibition. It reveals that the 
growth inhibitory function of Abl, similar to specific and pro- 
cessive tyrosine phosphorylation in vitro, requires an interplay 
between the cognate SH2 and tyrosine kinase domains. 
2. Materials and methods 
2.1. Plasmid constructions 
All constructs were derived from the original full-length Abl-Src 
chimeras of Mayer et al. [16]. Insertion of sequences ncoding the 
estrogen-receptor h rmone binding domain (HBD) was as described 
[17]. The retroviral vector pGDN [16], which was used for expression, 
differs only insignificantly from the one used in our previous tudies 
[10,17]. The indicated names refer both to the chimeric proteins them- 
selves and the retroviral vectors used for their expression i NIH 3T3 
fibroblast cells. Construct G:ER: fusion of the N-terminal 630 amino 
acids of c-Abl type IV lacking the SH3 domain to the HBD; the 
protein G:ER is identical to the one encoded by vector pPLAXB:ER 
in our previous tudy [17]. GSC:ER, GS:ER, and GSC-S:ER are 
derivatives of G:ER in which the tyrosine kinase domain, the SH2 
domain and both domains derive from c-Src. 
2.2. Cell culture, transfection, transformation a d growth inhibition 
assays 
Transfection ofNIH 3T3 cells, generation and propagation of clo- 
nal cell lines and determination f 'transformation' and 'inhibition of 
proliferation' was as described previously [10,11,17]. Where indicated 
13-estradiol was added at a final concentration f 0.1 ~M. 
2.3. Immunoblot analysis 
The preparation of protein extracts and immunoblotting of identi- 
cal amounts of total protein were essentially done as previously de- 
scribed [17]. The rat monoclonal antibody H222 (Abbott Labora- 
tories) and the mouse monoclonal anti-phosphotyrosine a tibody 
4G10 (UBI) were used to reveal fusion proteins containing the estro- 
gen-receptor HBD and proteins containing phosphotyrosine, r spec- 
tively. 
All rights reserved. 
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3. Results and discussion 
3. 1. Experimental strategy 
We took advantage of a series of Abl derivatives in which 
o~e or both of these domains (SH2 and tyrosine kinase) are 
replaced by the corresponding domain(s) of c-Src [16]. The 
tl msforming potential of these Abl-Src chimeras is activated 
d Le to deletion of the regulatory SH3 domain. These chimeras 
a e all able to transform NIH 3T3 fibroblast cells even though 
tte pattern of phosphotyrosinated c llular proteins hows dif- 
ft fences from one derivative to another. To study the growth 
iv hibitory activity of these chimeras, we fused them to the 
t-m BD of the estrogen receptor (ER). By analogy to our pre- 
v ously described Abl:ER fusion proteins [10,11], we expected 
tl e AbI-Src:ER chimeras to display their transforming and 
g~ owth inhibitory potential in the presence and in the absence 
o "estrogen, respectively. 
As depicted in Fig. 1, vectors for four fusion proteins cor- 
responding to all possible permutations of Abl and Src SH2 
a~d kinase domains were constructed. For simplified cross- 
rt ference we have based our nomenclature on the original 
ore of Mayer and Baltimore [16] for the Abl-Src chimeras. 
I aus, the parent retroviral construct G:ER encodes a fusion 
wotein consisting of the N-terminal 630 amino acids of c-Abl, 
h~cking the SH3 domain, fused to the ER HBD. Note that the 
potein encoded by G:ER is identical to AXB:ER described 
il our previous tudies with fusion proteins [10,17]. The rep- 
li,:ation-defective r troviral vectors encoding the four chi- 
neras were cotransfected into NIH 3T3 cells with a cloned 
lX ~oloney helper viral DNA as previously described [10,11,17]. 
lX!orphologically transformed foci were scored after 10 days. 
F ~ci appeared exclusively in the presence of hormone, indicat- 
i]g that the transforming function of all four fusion proteins 
as subjected to hormonal control by the ER HBD. More- 
o zer, all constructs induced similar numbers of foci per micro- 
g am of transfected DNA (~ 10-20#tg DNA). The latter re- 
sults agree qualitatively with those that were obtained with 
t} e same set of Abl-Src chimeras containing the whole C- 
t, rminal moiety of c-Abl instead of the ER HBD [16]. 
3 2. Morphological transformation correlates with tyrosine 
kinase activity and is hormone-dependent 
Several oci from each transfection were cloned by limiting 
d lution and maintained in the transformed state in the pres- 
e Lce of hormone. When viewed by phase-contrast microscopy 
(~:ig. 2; left panels), cells expressing any of the four chimeras 
ere round and refractile, and grew without apparent contact 
i] hibition. To examine the properties of Abl-Src:ER chimeras 
il the absence of hormone, cells were washed and incubated 
i] fresh medium without estrogens for 2 3 days. Remarkably, 
a l four types of cell lines reverted to normal morphology 
u)on removal of hormone. This finding is consistent with 
tl~e hormone-dependence of focus formation which we have 
o )served in the original focus assay. 
We have previously shown that hormone-dependent trans- 
f,,rmation by Abl:ER fusion proteins correlates with hor- 
n one-dependent tyrosine kinase activity [17]. We were inter- 
e~ted in whether this correlation also applied to the Abl- 
S'c:ER chimeras. Protein extracts were prepared from each 
c~'ll line grown in the absence and in the presence of hormone 
a~d identical amounts of total protein were displayed by SDS- 
PhGE electrophoresis. Tyrosine-phosphorylated proteins and 
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Fig. 1. Schematic representation f Abl derivatives and their biolog- 
ical properties. All four derivatives lack the Abl SH3 domain and 
are fused to the hormone binding domain (HBD) of the human es- 
trogen receptor at amino acid 630 of murine c-Abl type IV. SH2 
and tyrosine kinase domains are boxed; those denoted A and S de- 
rive from c-Abl itself and from c-Src, respectively. The column 
'Transformation' indicates whether a particular derivative induces 
morphologically transformed foci in the absence (-H) or in the 
presence (+H) of [3-estradiol. The column 'Inhibition of prolifera- 
tion' indicates whether overexpression leads to a block of cellular 
proliferation. 
the fusion proteins themselves were revealed by immunoblot- 
ting using antibodies against phosphotyrosine and the ER 
HBD, respectively (Fig. 3). The four fusion proteins are pres- 
ent at similar levels in the absence or in the presence of hor- 
mone although the levels of the chimeras are generally in- 
creased by hormone treatment (top panel in Fig. 3). In 
contrast, for all four fusion proteins, autophosphorylation 
of the fusion proteins and tyrosine phosphorylation f cellular 
proteins are dramatically increased upon hormone addition. 
However, the pattern of cellular proteins, which do become 
phosphorylated, appears to differ somewhat between different 
Abl-Src chimeras. In this respect, our fusion proteins with the 
ER HBD merely recapitulate what had already been observed 
with the original full-length Abl-Src chimeras [16]. This em- 
phasizes again that there may be different pathways to trans- 
formation or that the phosphorylation f very few common 
cellular targets is sufficient. 
The correlation between transformation a d tyrosine kinase 
activity is further strengthened bythe behavior of the chimera 
GSC S:ER in which both SH2 and tyrosine kinase domain 
are derived from Src. With this highly artificial protein hor- 
monal control imposed by the ER HBD seems to be some- 
what leaky; in the absence of hormone, tyrosine kinase activ- 
ity is clearly elevated relative to parental NIH 3T3 cells (Fig. 
3, bottom panel). This leakiness correlates with a slightly al- 
tered cell morphology (Fig. 2) compared to the parental cells, 
indicating partial transformation. 
3.3. Growth inhibition requires both the Abl SH2 and the Abl 
tyrosine kinase domains 
We have thus shown for all four chimeras that the trans- 
forming function can be switched off by removal of hormone. 
In the case of Abl:ER fusion proteins uch as G :ER, we knew 
that this results in the concomitant activation of the growth 
inhibitory function of Abl. By examining the proliferation of 
cell lines expressing the Abl-Src:ER chimeras GSC:ER, 
GS:ER and GSC S:ER after removal of hormone, we could 
now assess the role of the SH2 and the tyrosine kinase do- 
mains of Abl in growth inhibition. The effects of Abl-Src:ER 
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Fig. 2. Reversible morphological transformation f clonal cell lines. Cell lines expressing the AbI:ER fusion protein G:ER and the AbI-Src:ER 
fusion proteins GSC:ER, GS:ER and GSC-S:ER were grown in the presence (+H) or in the absence (-H) of 13-estradiol f r 48 h. Phase-con- 
trast micrographs show transformed and normal morphology, as defined by Jackson et al. [17], in the presence and in the absence of hormone, 
respectively. 
chimeras on proliferation were determined by establishing 
growth curves for clonal cell lines in the absence and in the 
presence of hormone. 
Fig. 4 shows the results for each of the four chimeras. For a 
given chimera, all clones, which were examined, showed the 
same behavior. In the presence of hormone, that is in the 
transformed state, cell lines expressing G:ER and Abl- 
Src:ER chimeras grow exponentially at similar rates. Subtle 
differences in growth rates, notably between GS :ER cells and 
cells expressing other chimeras, may be due to differential 
tyrosine phosphorylation of cellular target proteins which 
we have observed by our immunoblotting experiment with 
anti-phosphotyrosine a tibodies (see Fig. 3). Upon removal 
of hormone, a striking difference between G:ER and the other 
chimeras is revealed. As predicted, G:ER is switched to its 
growth inhibitory mode and completely blocks further prolif- 
eration. Although G:ER cells could be expected to progress 
through the cell cycle until they reach the point of G1 arrest, 
no further increase in G:ER cell numbers can be observed. As 
we have previously pointed out [10], it is conceivable that a 
fraction of cells undergoes cell death before the cells arrest in 
G1. In contrast, cells expressing Abl-Src:ER chimeras 
GS:ER, GSC:ER or GSC-S:ER continued to proliferate 
and doubled 3-5 times over a period of 6 days. The growth 
rates were slightly reduced in this particular set of experiments 
in the absence of hormone, but in other experiments, the 
growth rates of GS:ER, GSC:ER and GSC-S:ER cells 
were similar with and without hormone and comparable to 
that of the parental NIH 3T3 cells (data not shown). Given 
this variability, we cannot exclude that Abl-Src:ER chimeras 
GS:ER, GSC:ER and GSC-S:ER might retain a very low 
level of growth inhibitory activity. However, the dramatically 
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different growth properties of cells expressing G:ER or the 
Abl-Src chimeras trongly suggest hat a specific interplay 
oF the Abl SH2 and tyrosine kinase domains is essential for 
the growth inhibitory activity of Abl. 
We have now demonstrated that the growth inhibitory 
function of Abl requires both its SH2 domain and its tyrosine 
kinase domain. Mutants, in which one or the other or both 
domains are replaced by those of Src, lose their ability to 
il hibit proliferation. This suggests a specific interplay between 
ti e two domains. It has recently been shown that tyrosine 
k nases preferentially phosphorylate substrates recognized by 
t!~eir own SH2 and it was suggested that this increases ub- 
s~ rate specificity [18-20]. Indeed, Duyster et al. [18] and Mayer 
e al. [19] reported that the specificity and the processivity of 
tire Abl tyrosine kinase domain is dependent on the presence 
c. "its own SH2 domain. While these studies have established 
tie SH2-dependence of tyrosine kinases in their active state in 
tro, we have now extended the notion of interdependence of 
SH2 and SHI (tyrosine kinase domain) to the growth inhibi- 
t ,ry function of Abl in vivo. Substrate specificity can also be 
i~ fluenced by small adapter proteins uch as Crk and Grb2 
hich contain an SH2 domain and bind to Abl via their SH3 
comain [19,21]. Since all our chimeras contain the binding 
s tes for these adapter proteins, our results indicate that it is 
t~e SH2 domain of Abl itself which is necessary for growth 
i ~hibition. 
Interestingly, the growth inhibitory activities of wild-type c- 
~bl as well as Abl:ER fusion proteins correlate with very low 
t 'rosine kinase activity; nevertheless, a functional tyrosine 
l, tnase domain is absolutely required [6,13]. We have pre- 
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I ig. 3. The tyrosine kinase activities of Abl Src:ER chimeras are 
r~'gulated and very low in the absence of hormone. Immunoblot 
analysis of the chimeric proteins themselves and of total cellular 
phosphotyrosinated proteins. (Upper panel) The fusion proteins 
x~ere revealed with an antibody directed against the ER HBD. 
(Lower panel) Proteins containing phosphotyrosine w re revealed on 
the same blot. Note that Abl chimeras become strongly autophos- 
phorylated in the presence of hormone. The positions of molecular 
weight markers are indicated on the left. Arrows on the right mark 
the positions of the Abl chimeras which are all almost identical in 
s~ze. 
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Fig. 4. The substitution of the SH2 or the tyrosine kinase domains 
abolishes growth inhibition. Growth curves of clonal cell lines ex- 
pressing Abl:ER and Abl-Src:ER chimeras. Cells were washed and 
5000 to 10,000 cells were plated in each well of a 24-well plate, with 
(left panel +H) or without (right panel -H) ]3-estradiol; cells were 
counted at 1 day intervals tarting 48 h after plating. The graphs 
represent the average from two different clones for each of the chi- 
meras. Three independent experiments gave qualitatively identical 
results. 
viously speculated that growth inhibition may depend on 
non-catalytic nteractions of the tyrosine kinase domain or 
on low levels of tyrosine phosphorylation f target proteins. 
The additional requirement for the SH2 domain is compatible 
with both models. According to the first model, the SH2 do- 
main may help to capture target proteins which have already 
been phosphorylated, conceivably by other tyrosine kinases; 
this interaction might facilitate a non-catalytic interaction be- 
tween the Abl tyrosine kinase domain and the same target 
protein or even a third protein. An example of such a non- 
catalytic interaction has indeed been described: the retinoblas- 
toma protein Rb binds the ATP binding pocket of Abl and 
inhibits the tyrosine kinase activity in a cell-cycle-dependent 
way [3]. However, whether Rb binding is important for Abl- 
mediated growth inhibition remains unclear. While the pre- 
sence of Rb appears to be necessary for growth inhibition by 
Abl [13], binding alone is clearly not sufficient as exemplified 
by two types of mutants. Our chimera GS :ER, which contains 
the Abl tyrosine kinase domain and thus would be expected to 
bind Rb, fails to be growth inhibitory, and a point mutation 
in the kinase domain does not affect Rb binding [3] but 
abolishes growth inhibition [6,13]. 
The second model predicts that key target proteins would 
get phosphorylated by Abl despite the low overall kinase ac- 
tivity; the cognate SH2 domain might then bind these pro- 
teins and possibly preserve the tyrosine phosphorylation by 
preventing access of phosphatases. While a functional kinase 
is a prerequisite for this model, high stoichiometry and pro- 
cessivity of phosphorylation is not. Indeed, proteins which 
become specifically phosphorylated under growth inhibitory 
conditions cannot be detected by immunoblotting (see Fig. 
3). Both models predict that the interplay of the SH2 and 
SH1 domains leads to the assembly of a specific complex of 
key regulatory protein(s) on Abl. Growth inhibition could 
174 T. Mattioni et al./FEBS Letters 390 (1996) 170-174 
then result from the sequestration of factors or from the for- 
mation of such a complex. 
We hypothesize that the growth regulatory function of Abl 
revealed by our experiments i  a reflection of the normal role 
of the endogenous c-Abl. If this is the case, one would expect 
that Abl-Src chimeras would also fail to complement knock- 
out mice and flies. 
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